UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9312-9318

2005

Volltextzugriff (PDF)

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

Clinical cancer research, 2016-02, Vol.22 (4), p.993-999

2016

Volltextzugriff (PDF)

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

Breast cancer research and treatment, 2007-01, Vol.101 (1), p.113-121

2007

Volltextzugriff (PDF)

PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer

PloS one, 2021-11, Vol.16 (11), p.e0260124-e0260124

2021

Volltextzugriff (PDF)

A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers

Cancer cell, 2022-05, Vol.40 (5), p.479-493.e6

2022

Volltextzugriff (PDF)

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.611-622

2020

Volltextzugriff (PDF)

Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers

Clinical cancer research, 2020-12, Vol.26 (24), p.6568-6580

2020

Volltextzugriff (PDF)

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

JNCI : Journal of the National Cancer Institute, 2005-01, Vol.97 (1), p.30-39

2005

Volltextzugriff (PDF)

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer

Clinical cancer research, 2015-06, Vol.21 (11), p.2487-2498

2015

Volltextzugriff (PDF)

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

Clinical cancer research, 2016-07, Vol.22 (13), p.3121-3123

2016

Volltextzugriff (PDF)

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

Supportive care in cancer, 2022-10, Vol.30 (10), p.8059-8067

2022

Volltextzugriff (PDF)

Patient‐Reported Outcomes and Early Discontinuation in Aromatase Inhibitor‐Treated Postmenopausal Women With Early Stage Breast Cancer

The oncologist (Dayton, Ohio), 2016-05, Vol.21 (5), p.539-546

2016

Volltextzugriff (PDF)

Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer

Oral diseases, 2022-01, Vol.28 (1), p.193-201

2022

Volltextzugriff (PDF)

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Blood cancer discovery, 2021-11, Vol.2 (6), p.630-647

2021

Volltextzugriff (PDF)

Individualized Tamoxifen Dose Escalation-Response

Clinical cancer research, 2016-12, Vol.22 (24), p.6301-6301

2016

Volltextzugriff (PDF)

Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT

Cancer epidemiology, biomarkers & prevention, 2016-07, Vol.25 (7), p.1050-1058

2016

Volltextzugriff (PDF)

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

Breast cancer research and treatment, 2005-06, Vol.91 (3), p.249-258

2005

Volltextzugriff (PDF)

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B172 gene deletion

Breast cancer research and treatment, 2019-06, Vol.175 (2), p.297-303

2019

Volltextzugriff (PDF)

Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.623-623

2020

Volltextzugriff (PDF)

(−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Molecular cancer therapeutics, 2005-02, Vol.4 (2), p.197-205

2005

Volltextzugriff (PDF)

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.659-668

2017

Volltextzugriff (PDF)

Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy

Frontiers in oncology, 2021-01, Vol.10, p.601452

2021

Volltextzugriff (PDF)

Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance

Clinical cancer research, 2008-09, Vol.14 (18), p.5864-5868

2008

Volltextzugriff (PDF)

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer

Breast cancer research and treatment, 2013-04, Vol.138 (3), p.807-816

2013

Volltextzugriff (PDF)

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

Breast cancer research and treatment, 2012-02, Vol.131 (3), p.915-924

2012

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer

A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

Patient‐Reported Outcomes and Early Discontinuation in Aromatase Inhibitor‐Treated Postmenopausal Women With Early Stage Breast Cancer

Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer

Overcoming Acquired Epigenetic Resistance to BTK Inhibitors

Individualized Tamoxifen Dose Escalation-Response

Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B172 gene deletion

Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

(−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients

Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy

Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

Aktive Filter

Suchergebnisse filtern